Product: FAP Antibody
Catalog: AF5344
Description: Rabbit polyclonal antibody to FAP
Application: WB IHC IF/ICC
Cited expt.: WB, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 90-100kD, 65-70kD; 88kD(Calculated).
Uniprot: Q12884
RRID: AB_2837829

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(89%)
Clonality:
Polyclonal
Specificity:
FAP1 Antibody detects endogenous levels of total FAP.
RRID:
AB_2837829
Cite Format: Affinity Biosciences Cat# AF5344, RRID:AB_2837829.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

170 kDa melanoma membrane bound gelatinase; 170 kDa melanoma membrane-bound gelatinase; DPPIV; FAP; FAPA; Integral membrane serine protease; SEPR_HUMAN; Seprase;Prolyl endopeptidase FAP; Dipeptidyl peptidase FAP; Fibroblast activation protein alpha; FAPalpha; FAP alpha; Gelatine degradation protease FAP; Post-proline cleaving enzyme; Serine integral membrane protease; SIMP; Surface-expressed protease; Seprase;

Immunogens

Immunogen:

A synthesized peptide derived from human FAP, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Expression:
Q12884 SEPR_HUMAN:

Expressed in adipose tissue. Expressed in the dermal fibroblasts in the fetal skin. Expressed in the granulation tissue of healing wounds and on reactive stromal fibroblast in epithelial cancers. Expressed in activated fibroblast-like synoviocytes from inflamed synovial tissues. Expressed in activated hepatic stellate cells (HSC) and myofibroblasts from cirrhotic liver, but not detected in normal liver. Expressed in glioma cells (at protein level). Expressed in glioblastomas and glioma cells. Isoform 1 and isoform 2 are expressed in melanoma, carcinoma and fibroblast cell lines.

Sequence:
MKTWVKIVFGVATSAVLALLVMCIVLRPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWISGQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNASNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYLKQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATKYALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYPRTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVPAMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVLSICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITSGKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGSYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFSLSD

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Chicken
89
Xenopus
67
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as alpha-2-antiplasmin SERPINF2 and SPRY2. Degrade also gelatin, heat-denatured type I collagen, but not native collagen type I and IV, vibronectin, tenascin, laminin, fibronectin, fibrin or casein. Also has dipeptidyl peptidase activity, exhibiting the ability to hydrolyze the prolyl bond two residues from the N-terminus of synthetic dipeptide substrates provided that the penultimate residue is proline, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro. Natural neuropeptide hormones for dipeptidyl peptidase are the neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB). The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Plays a role in tissue remodeling during development and wound healing. Participates in the cell invasiveness towards the ECM in malignant melanoma cancers. Enhances tumor growth progression by increasing angiogenesis, collagen fiber degradation and apoptosis and by reducing antitumor response of the immune system. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner.

PTMs:

N-glycosylated.

The N-terminus may be blocked.

Subcellular Location:

Cell surface. Cell membrane>Single-pass type II membrane protein. Cell projection>Lamellipodium membrane>Single-pass type II membrane protein. Cell projection>Invadopodium membrane>Single-pass type II membrane protein. Cell projection>Ruffle membrane>Single-pass type II membrane protein. Membrane>Single-pass type II membrane protein.
Note: Localized on cell surface with lamellipodia and invadopodia membranes and on shed vesicles. Colocalized with DPP4 at invadopodia and lamellipodia membranes of migratory activated endothelial cells in collagenous matrix. Colocalized with DPP4 on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma. Anchored and enriched preferentially by integrin alpha-3/beta-1 at invadopodia, plasma membrane protrusions that correspond to sites of cell invasion, in a collagen-dependent manner. Localized at plasma and ruffle membranes in a collagen-independent manner. Colocalized with PLAUR preferentially at the cell surface of invadopodia membranes in a cytoskeleton-, integrin- and vitronectin-dependent manner. Concentrated at invadopodia membranes, specialized protrusions of the ventral plasma membrane in a fibrobectin-dependent manner. Colocalizes with extracellular components (ECM), such as collagen fibers and fibronectin.

Secreted.
Note: Found in blood plasma and serum.

Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in adipose tissue. Expressed in the dermal fibroblasts in the fetal skin. Expressed in the granulation tissue of healing wounds and on reactive stromal fibroblast in epithelial cancers. Expressed in activated fibroblast-like synoviocytes from inflamed synovial tissues. Expressed in activated hepatic stellate cells (HSC) and myofibroblasts from cirrhotic liver, but not detected in normal liver. Expressed in glioma cells (at protein level). Expressed in glioblastomas and glioma cells. Isoform 1 and isoform 2 are expressed in melanoma, carcinoma and fibroblast cell lines.

Family&Domains:

Belongs to the peptidase S9B family.

References

1). Spatial-Drug-Laden Protease-Activatable M1 Macrophage System Targets Lung Metastasis and Potentiates Antitumor Immunity. ACS nano, 2023 (PubMed: 36877635) [IF=15.8]

2). Microvesicle-inspired oxygen-delivering nanosystem potentiates radiotherapy-mediated modulation of tumor stroma and antitumor immunity. Biomaterials, 2022 (PubMed: 36257260) [IF=12.8]

3). Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics, 2023 (PubMed: 33664871) [IF=12.4]

4). FAP-catalyzed in situ self-assembly of magnetic resonance imaging probe for early and precise staging of liver fibrosis. Science advances, 2025 (PubMed: 40073128) [IF=11.7]

5). Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy. Journal of Nanobiotechnology, 2021 (PubMed: 34906155) [IF=10.2]

6). Cancer-associated fibroblasts secrete CSF3 to promote TNBC progression via enhancing PGM2L1-dependent glycolysis reprogramming. Cell Death & Disease, 2025 [IF=9.6]

7). Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma. International Journal of Biological Sciences, 2022 (PubMed: 35982904) [IF=8.2]

8). IL-17a promotes hepatocellular carcinoma by increasing FAP expression in hepatic stellate cells via activation of the STAT3 signaling pathway. Cell death discovery, 2024 (PubMed: 38740736) [IF=7.0]

Application: IF/ICC    Species: Human    Sample:

Fig. 2 IL-17a activates LX2 cell line, promotes their proliferation and migration, and inhibits their apoptosis. A Representative images indicating IL-17RA expression in the LX2 cell line. (Immunofluorescence staining, 200x, blue fluorescence, nuclei; red fluorescence, IL-17RA). B Representative images of quiescent (upper) and activated (lower) LX2 cells before and after IL-17a stimulation. C Cell proliferation curves of LX2 cells stimulated with 20 ng/ml IL-17a or treated with PBS, as determined by a CCK8 assay. D Proliferation rate of cells with IL-17a stimulation or PBS treatment, as determined by an EdU incorporation assay. E Representative images and statistical analysis of cell proliferation after IL-17a stimulation or PBS treatment by a plate colony formation assay. F Representative images of cell proliferation after IL-17a stimulation or PBS treatment, as shown by EdU incorporation (immunofluorescence staining, 200x, blue fluorescence, nuclei; red fluorescence, proliferating cells). G Representative images and statistical analysis of cell migration after IL-17a stimulation or PBS treatment in the Transwell assay. H Representative images of cell migration after IL-17a stimulation or PBS treatment in the wound healing assay. I Statistical analysis of wound closure after IL-17a stimulation or PBS treatment in the wound healing assay. J Apoptosis rate after IL-17a stimulation or PBS treatment, as determined by a TUNEL assay. K Representative images of apoptosis in the LX2 cell line after IL-17a stimulation or PBS treatment in the TUNEL assay (immunofluorescence staining, 200x, blue fluorescence, nuclei, green fluorescence, nuclei in cells undergoing apoptosis). L mRNA expression of several hepatic stellate cell-related genes in LX2 cell lines after IL-17a stimulation or PBS treatment. *, p 

9). Radiation-induced FAP + fibroblasts are involved in keloid recurrence after radiotherapy. Frontiers in Cell and Developmental Biology, 2022 (PubMed: 36092734) [IF=4.6]

10). Evaluation of a Novel Gd-FAPI Dimer Molecular Probe Targeting Fibroblast Activation Protein for Imaging of Solid Tumors. Molecular pharmaceutics, 2025 (PubMed: 39927594) [IF=4.5]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.